Background {#Sec1}
==========

Osteoarthritis (OA) is the most common form of arthritis. It is a major cause of disability among the ageing population. The affected joint is undergoing a complex combination of degradative and reparative processes (Collins et al. [@CR5]; Palazzo et al. [@CR23]), the mechanism of which is still unclear. There are currently no treatments that delay or halt OA progression.

The main clinical manifestations include pain, swelling and disability caused by topical cartilage loss, subchondral bony changes, osteophyte formation and synovitis (Liu et al. [@CR18]). OA has long been believed as a cartilage disease, but more recent evidence suggests that periarticular bone abnormality is also involved in the disease initiation and progression (Kalunian [@CR14]). Decreased bone mineral content and trabecular numbers in subchondral bone structure in the early OA have been observed by magnetic resonance imaging (Madry et al. [@CR19]). High-turnover type bone metabolism derangement has been considered as a main cause of OA (Collins et al. [@CR6]).

Previous experimental studies on bone anti-resorptive agents for OA have shown promising results (Fenty et al. [@CR8]). The Duncan-Hartley guinea pig model is a widely used spontaneous model of OA progression, which is characterized by subchondral bony changes (Sun et al. [@CR30]). In rat anterior cruciate ligament transection (ACLT) models of KOA, alendronate could protect cartilage from degeneration and inhibit subchondral bone remodeling (Strassle et al. [@CR29]).

Bisphosphonates can inhibit bone resorption and therefore they are the mainstream medications for osteoporosis. But for OA treatment, there is no official statement or guideline for bisphosphonates therapy. Recently, more and more evidence have shown bisphosphonates are effective in OA treatment. Bisphosphonates can suppress local bone turnover or inhibit the level of local pro-inflammatory cytokines. Further studies confirmed that defective subchondral bone metabolism in OA could alter chondrocytes during subchondral bone remodeling. Increased subchondral bone turnover may contribute to pain in OA, which may be relieved by targeting osteoclasts. Although bisphosphonates therapy seems to have positive effects on OA, these effects have not been extensively studied. To our knowledge, only one systematic review and meta-analysis was conducted with a limited number of poor-quality RCTs, which demonstrated limited evidence of bisphosphonates for pain relief in OA (Davis et al. [@CR7]). Moreover, osteoarthritis progression, required acetaminophen treatment and joint replacement were not analyzed.

Therefore, this review aims to summarize the results of these clinical trials and evaluate the clinical effects, which may be useful to clinical practice. This meta-analysis was conducted in accordance with Cochrane guidelines (Higgins and Green [@CR12]).

Methods {#Sec2}
=======

Search strategies {#Sec3}
-----------------

All searches were conducted from database MEDLINE, PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to February 28, 2016. The MeSH terms we used were (Osteoarthritis) AND (OA) AND (Bisphosphonates). To ensure a more complete meta-analysis, we used a maximally sensitive search for RCTs according to the Cochrane Highly Sensitive Search Strategy. Systematic review and meta-analysis were manually searched as references for included studies.

Inclusion criteria {#Sec4}
------------------

The inclusion criteria were (1) RCTs comparing bisphosphonates with any control methods, include a placebo or a conventional medication. And published as peer-reviewed indexed papers; (2) patients with established OA administering medication or other control interventions; (3) studies detailing the type and dosage of medications and treatment course; (4) primary outcomes included visual analogue scale (VAS) pain score, WOMAC pain, stiffness, function score and osteophyte score, while secondary outcomes included subjective improvement, osteoarthritis progression and the number of required acetaminophen treatment or joint replacement. Studies reported at least two of the primary outcomes. (5) Literature in English.

Exclusion criteria {#Sec5}
------------------

The exclusion criteria were (1) non-randomized controlled trials; (2) studies without available data; (3) duplicate publications among authors or centers.

Data extraction and quality assessment {#Sec6}
--------------------------------------

Data from all eligible papers were extracted and independently verified. Data extracted included study characteristics, patient characteristics, primary and secondary outcomes.

Study characteristics included study design, name of first author, sample size and follow-up period. Patient characteristics included the number of patients, gender, affected joint, type of intervention and dosage. If a study reported the outcomes of multiple doses of bisphosphonates, only data of the maximum dose were extracted for analysis. If a study reported the outcomes of multiple time points after treatment, only data of the final follow-up time point was extracted for analysis.

The methodological quality of each included study was evaluated in accordance with the Cochrane Collaboration's risk of bias tool (Higgins and Green [@CR12]), which used the following items as random sequence generation, allocation concealment, blinding of outcome assessors,patients and other participants, incomplete outcome data, selective reporting of outcomes and other biases. The bias risk of each item was graded as low, high or unclear.

Statistical analysis {#Sec7}
--------------------

All statistical analyses were conducted with RevMan version 5.3 software (provided by Cochrane Collaboration). Heterogeneity was evaluated with Q tests and *I*^2^, and P \< 0.10 was determined as significant. If there was no or low heterogeneity then the fixed-effects model was used. Otherwise, the random-effects model was used. The risk ratio (RR) was calculated for dichotomous data, and weighted mean differences (WMD) or standard mean differences (SMD) were used for continuous variables. Both differences were presented with 95 % CI. For continuous variables, if data were presented with medians and ranges, then the means and SDs were calculated according to Hozo et al. ([@CR13]). If the study presented the median and interquartile range, the median was treated as the mean, and the interquartile ranges were calculated using 1.35 SDs, as described in the Cochrane handbook.

Results {#Sec8}
=======

Search results {#Sec9}
--------------

The results of the literature search strategy identified a total of 1145 papers. 294 full texts were reviewed and a total of 15 papers were deemed eligible and included in this systematic review (covering a total of 3566 patients, including 1517 in bisphosphonates group and 2049 in control groups) (Fig. [1](#Fig1){ref-type="fig"}). (Neogi et al. [@CR21]; Rossini et al. [@CR25]; Laslett et al. [@CR17]; Nishii et al. [@CR22]; Arti and Azemi [@CR1]; Laslett et al. [@CR16]; Saviola et al. [@CR26]; Fujita et al. [@CR11]; Rossini et al. [@CR24]; Fujita et al. [@CR10]; Bingham et al. [@CR2]; Spector et al. [@CR28]; Carbone et al. [@CR4]; Fujita et al. [@CR9]).Fig. 1Flow chart of study selection

Characteristics of included studies {#Sec10}
-----------------------------------

Of the 15 eligible studies, 1517 patients received bisphosphonates therapy, and 2049 patients received control interventions. The baseline characteristics were similar among these trials (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of 15 RCTs includedAuthorsStudy designNumber of patientsAge\
(year)Affected jointDiagnostic criteriaDuration\
(month)Outcome meatureDrugsNeogi et al. ([@CR21])Randomised case--control20065.8 ± 6.1\
66.1 ± 6.4SpineRadiographs24OST, DSNAlendronate VS placeboRossini et al. ([@CR25])Double-blind randomized8066 ± 6KneeRadiographs3WOMAC, VASClodronate VS placeboLaslett et al. ([@CR17])Observational cohort study32359.8 ± 8\
66.7 ± 7.4KneeRadiographs60VAS, WOMAC, JSWBisphosphonates used VS Non-usersNishii et al. ([@CR22])Non-blinded randomised4254.7 ± 8.5\
58.3 ± 8.8HipRadiographs24WOMAC, VAS, JSWAlendronate VS calcium lactateArti and Azemi ([@CR1])Double-blind randomized13060.9 ± 9.9KneeRadiographs3WOMACAlendronate VS glucosamineLaslett et al. ([@CR16])Double-blind randomised5364.2 ± 8.2\
60.4 ± 7.3KneeRadiographs12VAS,KOOS;Zoledronic VS placeboSaviola et al. ([@CR26])Non-randomised case control2960.0 ± 7.1\
63.5 ± 7.4HandRadiographs24VAS, HS, NOSPJClodronate VS HCQFujita et al. ([@CR11])Randomised case--control3869 ± 8\
68 ± 9Spine, kneeRadiographs6VAS, SF-36Risedronate VS ElcatoninRossini et al. ([@CR24])Partially blinded randomised15064.7 ± 7.4\
65.2 ± 6.9KneeRadiographs18VAS, LIClodronate VS Hyaluronic acidFujita et al. ([@CR10])Non-randomised case--control10068 ± 9.0\
66 ± 8.0Spine, kneeRadiographs7VASAlendronate VS CalciumBuckland-Wright ([@CR100])Double-blind randomized62760.3 ± 2.6\
63.1 ± 2.3KneeRadiographs24JSWRisedronate VS placeboBingham et al. ([@CR2])Double-blind randomized248360.7 ± 0.5\
60.2 ± 0.5KneeRadiographs24WOMAC, JSW,Risedronate VS placeboSpector et al. ([@CR28])Double-blind randomised28563.8 ± 0.9\
63.2 ± 0.8KneeRadiographs12WOMAC; PGARisedronate VS placeboCarbone et al. ([@CR4])Cross sectional cohort study81874.8 ± 2.9\
74.8 ± 2.9KneeRadiographs36Modified WOMACAlendronate VS placeboFujita et al. ([@CR9])Non-blinded randomised,8065 ± 7Spine, kneeRadiographs12VASEtidronate VAS placebo*OST* spinal osteophytes, *DSN* disc-space narrowing, *WOMAC* Western Ontario McMaster Universities (WOMAC) Osteoarthritis Index, *VAS* Visual Analogue Scale, *JSW*: joint space width, *HS* hand strength, *NOSPJ* number of swollen and painful joints, *PGA* Patient Global Assessment, *LI* Lequesne Index, *KOOS* Knee Injury and OA Outcome Score

Methodological quality of studies {#Sec11}
---------------------------------

The quality assessment of the trials was performed using the Cochrane Collaboration's Risk of Bias tool. The results of quality assessment illustrated there were some methodological limitations in these studies, quality of which was moderate (Fig. [2](#Fig2){ref-type="fig"}). Random sequence generation was described clearly in 6 studies (40 %) and unclearly in 8 studies (53 %). 3 studies (20 %) had a high risk of bias relating to allocation concealment, and 12 studies (80 %) had an unclear risk of bias relating to allocation concealment. Only 7 studies (46.7 %) blinded outcome assessors and the blindness in 5 studies (33.3 %) were unclear. All RCTs had a low risk of bias relating to incomplete outcome data and selective reporting. Biases relating to other aspects were unclear.Fig. 2Methodological quality assessment according to the Cochrane Collaboration's Risk of Bias tool study

Meta-analysis {#Sec12}
=============

Primary outcome parameters {#Sec13}
--------------------------

VAS pain score: the results of 6 studies (627 patients) with combined data indicated that bisphosphonates therapy improved pain nosignificantly assessed by VAS pain scores (MD = 0.80; 95 % CI −1.13 to 2.73; P = 0.42) compared with respective control group (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Change of Visual Analogue Scale (VAS) Pain Score

WOMAC pain score: the results of 5 studies (1879 patients) with combined data indicated that bisphosphonates therapy improved pain significantly assessed by WOMAC pain score (MD = 4.59; 95 % CI 2.83--6.34; P \< 0.00001) compared with respective control group (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Change of WOMAC-Pain. The first Bingham et al. ([@CR2]) refers to the outcomes from 44 European centers (11 countries), the second Bingham refers to the outcomes from 42 centers in North America (US and Canada); The first Rossini et al. ([@CR25]) refers to the outcomes of 8 weeks follow-up, the second Rossini et al. ([@CR25]) refers to the outcomes of 16 weeks follow-up

WOMAC stiffness score: the results of 3 studies (1757 patients) with combined data indicated that bisphosphonates therapy improved stiffness in affected joints significantly assessed by WOMAC stiffness score (MD = 1.43; 95 % CI 0.83--2.23; P = 0.0005) compared with respective control group (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Change of WOMAC-Stiffness. The first Bingham et al. ([@CR2]) refers to the outcomes from 44 European centers (11 countries), the second Bingham refers to the outcomes from 42 centers in North America (US and Canada)

WOMAC function score: the results of 3 studies (1757 patients) with combined data indicated that bisphosphonates therapy improved the function of affected joints significantly assessed by WOMAC function scores (MD = 2.01; 95 % CI 1.27--2.75; P \< 0.00001) compared with respective control group (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Change of WOMAC-Function. The first Bingham et al. ([@CR2]) refers to the outcomes from 44 European centers (11 countries), the second Bingham refers to the outcomes from 42 centers in North America (US and Canada)

Osteophyte score: the results of 4 studies (1125 patients) with combined data indicated that bisphosphonates therapy relieved osteophyte formation in affected joints significantly assessed by osteophyte score (MD = −0.51; 95 % CI −0.84 to −0.19; P = 0.002) compared with respective control intervention (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Change of Osteophyte Score. The first Neogi et al. ([@CR21]) refers to the outcomes of adjusted change in summary osteophyte score, the second Neogi et al. ([@CR21]) refers to the outcomes of adjusted change in summary disc-space narrowing score

Secondary outcome {#Sec14}
-----------------

There were no significant differences in osteoarthritis progression (3 studies including 2578 patients), required acetaminophen treatment (3 studies including 940 patients) and joint replacement (3 studies including 424 patients) between the application of bisphosphonates therapy and respective control intervention (Figs. [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}).Fig. 8clinical improvement rateFig. 9Joint replacement rateFig. 10Patients required acetaminophen treatmentFig. 11Osteoarthritis progression rate

Discussion {#Sec15}
==========

This meta-analysis demonstrated bisphosphonates therapy in OA had better effect on joint pain, stiffness and function, although it had no better effect on osteoarthritis progression, required acetaminophen treatment and joint replacement comparing to other medications. However, there was some heterogeneity across the included studies as for pain, stiffness and function scores, which may result from variation in the types or doses of bisphosphonates in different studies. When a sensitivity analysis was performed, the heterogeneity disappeared.

Current pharmacologic therapies for OA aim majorly to symptom control with analgesics, non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors (Smith et al. [@CR27]). NSAIDs, a most commonly used medication in symptomatic OA management, are found to be associated with gastrointestinal adverse reaction dose-related risks of renal toxicity and cardiovascular diseases (Brown [@CR3]). Glucosamine has been suggested as a potential structure-modifying OA drug, but the data concerned are inconsistent (Krader [@CR15]). Increased evidence suggests that high turnover metabolism derangement plays an important role in the initiation and progression of OA, which has resulted in an increased level of interest in drugs that affecting bone metabolism may slow the progression of OA (McGrory et al. [@CR20]).

Based on 15 RCTs, this meta-analysis indicated that bisphosphonates therapy have better effect in relieving pain and accelerating functional recovery for OA. In our study, there were no significant differences on the number of required acetaminophen treatment and joint replacement between bisphosphonates therapy and other conventional medications. But the causes that patients received NSAID were various, and few researchers provided the details of clinical stage and pathological grade of their patients. Therefore, further studies are needed to provide more solid evidence.

Quality of the evidence {#Sec16}
=======================

The overall methodological quality was moderate, and most studies had at least one aspect of unclear or high risk of bias. Not all outcome assessors were blinded, which may produce performance or measurement biases. Selection bias may exist since only 3 studies used allocation concealment. As bisphosphonates are only be evaluated as "off label" therapy for OA, there was no corresponding standardized treatment guideline. Although we had performed sensitivity analysis, the effect of bisphosphonates may be underestimated.

Conclusions {#Sec17}
===========

This meta-analysis showed that bisphosphonates therapy is effective for patients with OA in relieving pain and accelerating functional recovery. However, the conclusions are limited due to small sample sizes and methodological study quality, the different doses and treatment courses among studies. Further studies are needed to provide more solid evidence.
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